Coeliac Disease Vaccine

the need | Nexvax2 | our technology | clinical trial | references

References

1. Bardella MT, Velio P, Cesana BM, Prampolini L, Casella G, Di Bella C, Lanzini A, Gambarotti M, Bassotti G, Villanacci V. Coeliac disease: a histological follow-up study. Histopathology 2007; 50: 465-71.
2. Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, Biagi F, Volta U, Accomando S, Picarelli A, De Vitis I, Pianelli G, Gesuita R, Carle F, Mandolesi A, Bearzi I, Fasano A. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85:160-6.
3. Kaukinen K, Peräaho M, Lindfors K, Partanen J, Woolley N, Pikkarainen P, Karvonen AL, Laasanen T, Sievänen H, Mäki M, Collin P. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007; 25: 1237-45.
4. Larche M, Wraith DC: Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11: S69-76.
5. Durham, S.R., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341, 468-475.
6. Lundin, K.E., et al. Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. Journal of Experimental Medicine 178, 187-196 (1993).
7. Molberg O, Mcadam SN, Körner R, Quarsten H, Kristiansen C, Madsen L, Fugger L, Scott H, Norén O, Roepstorff P, Lundin KE, Sjöström H, Sollid LM. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4: 713-17.
8. Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, Ciclitira PJ, Sollid LM, Partanen J; European Genetics Cluster on Celiac Disease. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003; 64: 469-7.
9. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV: In vivo antigen challenge in coeliac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine 2000;6:337-342.
10. Anderson RP, van Heel DA, Tye-Din JA, Barnardo M, Salio M, Jewell DP, Hill AV: T cells in peripheral blood after gluten challenge in coeliac disease. Gut 2005;54:1217-1223.
11. Beissbarth T, Tye-Din JA, Smyth GK, Speed TP, Anderson RP: A systematic approach for comprehensive T-cell epitope discovery using peptide libraries. Bioinformatics 2005;21 Suppl 1:i29-37.
12. Dube, C., et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 128, S57-67 (2005).
13. Fasano, A., et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Archives of Internal Medicine 163, 286-292 (2003).
14. Tye-Din, J. & Anderson, R. Immunopathogenesis of celiac disease. Current gastroenterology reports 10, 458-465 (2008).
15. Anderson, R.P. Coeliac disease: current approach and future prospects. Internal medicine journal 38, 790-799 (2008).
16. Anderson, R.P. Coeliac disease. Australian Family Physician 34, 239-242 (2005).